Ann: Appendix 4E & Annual Report, page-13

An ongoing project for me and many of you I am sure as more information emerges. I am no medical reimbursement expert. It doesn't help that we have no reliable market pricing for Striate/Remplir - that no one on here can get a professional dentistry/maxillofacial friend to look up BioHorizons prices is a bit disappointing.

DVT's product website doesn't even have Remplir listed. Clearly the 682 sales come from existing sales routes and simply supplied by DVT. Another example of disappointing business tardiness, but that they achieved such raped growth in Remplir sales without the product even being formally listed on DVT's online catalogue, says the revenue potential for Australia and Remplir has barely been scratched.

This is very simplified, but for those who didn't work it out, if you took the Appendix 4C's units sales figures as verbatim and the accrued revenues, taking a $1,354 revenue price for Remplir (per the reimbursement schedule) it would give you around $93 average revenue on Striate:

($1,354 x 682 Remplir) + ($93 x 10936 Striate) = $194K

Obviously no way that simple. But it gives investors on here an idea. Taking a more conservative actual average revenue on Remplir units to OCC might give you something like:

($1,000 x 682 Remplir) + ($115 x 10936 Striate) = $194K

For those who don't recall OCC reported very rapid overall, but variable by quarter, sales increases in their Appendix 4C for this year:

	FY23
1	Qtr		Sriate	Remplir
2	4		5482	362
3	3		2339	100
4	2		2726	36
5	1		389	184
6
7	FY23		10936	682